These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 20470240)

  • 1. Nonpigmented fixed drug eruption induced by esomeprazole.
    Morais P; Baudrier T; Mota A; Cunha AP; Cadinha S; Barros AM; Azevedo F
    Cutan Ocul Toxicol; 2010 Sep; 29(3):217-20. PubMed ID: 20470240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lichenoid drug eruption.
    Brauer J; Votava HJ; Meehan S; Soter NA
    Dermatol Online J; 2009 Aug; 15(8):13. PubMed ID: 19891921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors.
    Almebayadh M; Regnier-Rosencher E; Carlotti A; Goulvestre C; Le Guern V; Mouthon L; Avril MF; Dupin N
    Dermatology; 2013; 226(2):119-23. PubMed ID: 23548825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole-induced hallucinations. Not as rare as you might think.
    Sebastián Domingo JJ
    Gastroenterol Hepatol; 2018 Apr; 41(4):266-267. PubMed ID: 28625416
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacology of esomeprazole and its role in gastric acid related diseases.
    Saccar CL
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1113-24. PubMed ID: 19606942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of esomeprazole, compared with omeprazole, in maintenance therapy for reflux esophagitis -a phase III, multicenter, randomized, double-blind trial-].
    Kinoshita Y; Miwa H; Kasugai K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Aug; 110(8):1428-38. PubMed ID: 23912002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed drug eruption in hands caused by omeprazole.
    Kepekci Y; Kadayifci A
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):307-9. PubMed ID: 10395123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic colitis associated with omeprazole and esomeprazole exposure.
    Wilcox GM; Mattia AR
    J Clin Gastroenterol; 2009 Jul; 43(6):551-3. PubMed ID: 19142168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole fixed drug eruption.
    Salloum A; Nasr D; Maalouf D
    Contact Dermatitis; 2020 May; 82(5):334-335. PubMed ID: 31967328
    [No Abstract]   [Full Text] [Related]  

  • 14. Late hypersensitivity to omeprazole and other proton pump inhibitors.
    Pirson F; Geubel A; Marot L
    Acta Clin Belg; 2012; 67(4):301-3. PubMed ID: 23019809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of esomeprazole compared with omeprazole in reflux esophagitis patients -a phase III, multicenter, randomized, double-blind, parallel-group trial-].
    Kinoshita Y; Miwa H; Kasugai K
    Nihon Shokakibyo Gakkai Zasshi; 2013 Feb; 110(2):234-42. PubMed ID: 23381211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esomeprazole magnesium (Nexium).
    Baker DE
    Rev Gastroenterol Disord; 2001; 1(1):32-41. PubMed ID: 12120118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rapidity of pain relief, medication requirement and patient satisfaction with reflux treatment in the physician's office].
    Dohmen W; Fuchs W
    MMW Fortschr Med; 2005 Apr; 147 Suppl 1():21-5. PubMed ID: 16739368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of cross reactivity between proton pump inhibitors].
    Hammami S; Affes H; Ksouda K; Feki M; Sahnoun Z; Zeghal KM
    Therapie; 2013; 68(6):361-8. PubMed ID: 24356187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esomeprazole: a proton pump inhibitor.
    Vachhani R; Olds G; Velanovich V
    Expert Rev Gastroenterol Hepatol; 2009 Feb; 3(1):15-27. PubMed ID: 19210109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.